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Background: Drug transporters play important roles in the absorption, distribution, and elimination of drugs and
thereby, modulate drug efficacy and toxicity. With a growing use of poly pharmacy, concurrent administration of
herbal extracts that modulate transporter activities with drugs can cause serious adverse reactions. Therefore,
prediction and evaluation of drug-drug interaction potential is important in the clinic and in the drug development
process. DA-9801, comprising a mixed extract of Dioscoreae rhizoma and Dioscorea nipponica Makino, is a new
standardized extract currently being evaluated for diabetic peripheral neuropathy in a phase II clinical study.
Method: The inhibitory effects of DA-9801 on the transport functions of organic cation transporter (OCT)1, OCT2,
organic anion transporter (OAT)1, OAT3, organic anion transporting polypeptide (OATP)1B1, OATP1B3, P-glycoprotein
(P-gp), and breast cancer resistance protein (BCRP) were investigated in HEK293 or LLC-PK1 cells. The effects of
DA-9801 on the pharmacokinetics of relevant substrate drugs of these transporters were also examined in vivo in rats.
Results: DA-9801 inhibited the in vitro transport activities of OCT1, OCT2, OAT3, and OATP1B1, with IC50 values of 106,
174, 48.1, and 273 μg/mL, respectively, while the other transporters were not inhibited by 300 μg/mL DA-9801. To
investigate whether this inhibitory effect of DA-9801 on OCT1, OCT2, and OAT3 could change the pharmacokinetics
of their substrates in vivo, we measured the pharmacokinetics of cimetidine, a substrate for OCT1, OCT2, and OAT3, and
of furosemide, a substrate for OAT1 and OAT3, by co-administration of DA-9801 at a single oral dose of 1,000 mg/kg.
Pre-dose of DA-9801 5 min or 2 h prior to cimetidine administration decreased the Cmax of cimetidine in rats. However,
DA-9801 did not affect the elimination parameters such as half-life, clearance, or amount excreted in the urine, suggesting
that it did not inhibit elimination process of cimetidine, which is governed by OCT1, OCT2, and OAT3. Moreover, DA-9801
did not affect the pharmacokinetic characteristics of furosemide, as evidenced by its unchanged pharmacokinetic
parameters.
Conclusion: Inhibitory effects of DA-9801 on OCT1, OCT2, and OAT3 observed in vitro may not necessarily translate
into in vivo herb-drug interactions in rats even at its maximum effective dose.
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Diabetic peripheral neuropathy is one of the most
debilitating complications of type 1 and type 2 diabetes and
its histopathology is characterized by axonal degeneration,
demyelination, and atrophy [1,2]. Approximately 50% of
diabetes patients have symptoms of diabetic peripheral
neuropathy [3]. The pursuit of new drugs for the
treatment of diabetic peripheral neuropathy has led to
the identification of DA-9801, an ethanol extract of
Dioscoreae rhizoma and Dioscorea nipponica Makino,
as a potential therapeutic agent; it is currently being
evaluated in a phase II diabetic neuropathy clinical
study in Korea [4]. DA-9801 may improve diabetic
neuropathy-induced tissue damage by increasing nerve
growth factor levels in target tissues, improving nerve
conduction velocity, and promoting recovery from
neuronal degeneration [4,5]. It also showed neuroprotective
effects on peripheral nerves in streptozotocin-induced
diabetic rats [6,7].
Herb-drug interactions, resulting from concurrent use
of herbal drugs may cause adverse reactions such as
toxicity and treatment failure [8]. The mechanisms
underlying herb-drug interactions involve inhibition
or induction of cytochrome P450 (CYP) enzymes,
UDP-glucuronosyltransferase (UGT) enzymes, and drug
transporters [9,10]. St. John’s wort (Hypericum perforatum),
ginkgo (Ginko biloba), ginseng (Panax ginseng), milk thistle
(Silybum marianum), and licorice (Glycyrrhiza glabra)
have been reported to cause drug interactions with
anticoagulants, antiretroviral drugs, anticancer drugs,
immunosuppressants, or antidepressants [11-15]. Therefore,
it is necessary to evaluate herb-drug interactions in order to
prevent potentially dangerous clinical outcomes. DA-9801
did not potently inhibit CYP 1A2, 2A6, 2B6, 2C8, 2C9,
2C19, 2D6, or 3A4 and UGT 1A1, 1A4, 1A9, or 2B7
in human liver microsomes, indicating that DA-9801 may
not inhibit the metabolism of CYP- and UGT-catalyzed
drugs in humans [8].
In this study, we investigated possible herb-drug interac-
tions involving drug transporters by using HEK293 and
LLC-PK1 cell systems overexpressing clinically important
uptake and efflux transporters such as organic cation trans-
porter (OCT) 1, OCT2, organic anion transporter (OAT) 1,
OAT3, organic anion transporting polypeptide (OATP)
1B1, OATP1B3, P-glycoprotein (P-gp or MDR1), and breast
cancer resistance protein (BCRP) [16]. We also investigated
the effects of DA-9801 on the pharmacokinetics of
substrates for the effected transporters in vivo in rats.
Methods
Chemicals and reagents
Dried Dioscoreae rhizoma and rhizome of Dioscorea
nipponica Makino were purchased at a speciality market
for traditional herbal medicine (Dong Kyung Pharm. Co.,Seoul, Korea) and their identity was kindly confirmed by
Prof. Yeong Bae Seo (a specialist in plant classification,
Natural Products Research Institute, Seoul National
University, Seoul, Korea). The voucher specimens for
Dioscoreae rhizoma (deposit code, KNJS) and rhizome
of Dioscorea nipponica Makino (deposit code, LY026)
were deposited at Dong-A ST Research Center (Youngin,
Korea).
DA-9801 was prepared as previously reported [5]. Briefly,
dried Dioscoreae rhizoma and rhizome of Dioscorea
nipponica Makino were mixed in a specific ratio
(3.5:1) and extracted with 50% ethanol three times at
room temperature for 48 h. After filtration, the aqueous
ethanol extract was evaporated under reduced pressure
and lyophilized to completely remove the residual solvent
and to yield brown powder. The levels of two marker
components - dioscin (1.37%) and allantoin (3.29%) - in
DA-9801 were determined using high performance liquid
chromatography [5].
[3H]Methyl-4-phenylpyridinium (MPP+, 2.9 TBq/mmol),
[3H]para-aminohippuric acid (PAH, 0.13 TBq/mmol), [3H]
estrone-3-sulfate (ES, 2.12 TBq/mmol), [3H]digoxin (1.103
TBq/mmol) and [3H]estradiol-17β-D-glucuronide (EG,
2.22 TBq/mmol) were purchased from Perkin Elmer Inc.
(Boston, MA, USA). Cimetidine, furosemide and tiapride
were obtained from Sigma-Aldrich Co. (St. Louis, MO,
USA). 4-Hydroxydiclofenac-d4 was obtained from Toronto
Research Chemicals Inc. (North York, Ontario, Canada).
All other chemicals were reagent grade and all solvents
were HPLC grade.
Inhibitory effects of DA-9801 on transport activities
HEK293 cells transiently overexpressing OAT1, OAT3,
OCT1, OCT2, OATP1B1, and OATP1B3 transporters
were purchased from Corning-Gentest (Tewksbury, MA,
USA). The cells were maintained at 37°C in a humidified
atmosphere of 8% CO2, in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum, 5 mM
non-essential amino acids, and 100 U/mL penicillin–
streptomycin. For experiments, 105 cells were seeded
in 96-well plates. After 24 h, the growth media were
discarded and the attached cells were washed with
Hank’s balanced salt solution (HBSS) and preincubated
for 20 min in HBSS at 37°C. To examine the effects of
DA-9801 on transporter activity, the uptake of 0.1 μM
[3H]MPP+ for OCT1 and OCT2, 1 μM [3H]PAH for
OAT1, 0.1 μM [3H]ES for OAT3 and OATP1B1, and
0.1 μM [3H]EG for OATP1B3 was measured in the
presence of DA-9801 (1–300 μg/mL) for 10 min at
37°C. The cells were then washed three times with
100 μL of ice-cold HBSS immediately after placing the
plates on ice and lysed with 10% SDS. The radioactivity
of the probe substrate in the cells was measured using a
liquid scintillation counter.
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purchased from Corning-Gentest) and LLC-PK1-BCRP
(LLC-PK1 cells stably expressing BCRP; obtained from Dr.
A.H. Schinkel, Netherlands Cancer Institute, Amsterdam,
The Netherlands) cells were used for the comparison of the
basal to apical (B to A) transport rate of [3H]digoxin and
[3H]ES in the absence and presence of DA-9801. Briefly,
the cells were seeded on filter inserts for 24-transwell plates
at a density of 5 × 105 cells and grown for 5 days.
The integrity of the cell monolayers was evaluated
prior to transport experiments by measuring transepithelial
electrical resistance (TEER) and TEER values in the range
of 300–850 Ω · cm2 were used in the transport experiment
[17]. For measurement of B to A transport, 0.8 mL of HBSS
containing [3H]digoxin or [3H]ES (0.1 μM each) and
DA-9801 (1–300 μg/mL) was added on the basal side,
and 0.3 mL of fresh HBSS was added on the apical
side. At every 15 min, 0.2 mL of HBSS sample in the
apical side was removed and replaced with 0.2 mL of
fresh HBSS for 1 h.
Effect of DA-9801 pretreatment on the pharmacokinetics
of cimetidine and furosemide in rats
Sprague–Dawley (SD) rats (male, 7 weeks old) were
obtained from Samtako Co. (Osan, Korea). Animals were
acclimated for 1 week in a temperature controlled room
(23 ± 2°C), with a relative humidity of 55 ± 10%, an
illumination intensity of 150–300 lux, a frequency of air
ventilation of 15–20 times/h, and a 12 h illumination
(07:00–19:00). Food and water were supplied ad libitum.
All animal procedures were approved by the Animal Care
and Use Committee in The Catholic University of Korea.
Rats were cannulated with polyethylene tubing (PE-50,
Natsume Co, Tokyo, Japan) in the jugular vein for sampling
under anesthesia with isoflurane. Each rat was housed
individually in a rat metabolic cage and allowed to recover
from anesthesia. The rats were not restrained at any time
during the study. Heparinized isotonic saline (10 U/mL)
was used to flush the catheters to prevent blood clotting.
The rats were fasted for more than 12 h before oral
administration of drugs.
DA-9801 was dissolved in DMSO/propylene glycol/
deionized water (2:6:2, v/v), and a 1,000 mg/kg dose
was administered to the rats by oral gavages (vehicle
dosing volume, 3 mL/kg) at 5 min and 2 h prior to the
oral administration of cimetidine at a dose of 10 mg/kg
[18] and furosemide at a dose of 10 mg/kg [19] (vehicle
dosing volume, 2 mL/kg). Cimetidine and furosemide
were dissolved in deionized water and DMSO/propylene
glycol/deionized water (2:4:4, v/v/v), respectively. Blood
samples were collected prior to cimetidine and furosemide
administration (to serve as a control), 5, 15, 30, 45 min,
and 1, 1.5, 2, 3, 4, 6, 8 h after oral administration of
cimetidine and furosemide. After centrifugation of bloodsamples at 13,000 rpm for 5 min, plasma samples (30 μL)
were collected and stored at −80°C until analysis. At 24 h
after drug administration, the metabolic cage was rinsed
with distilled water (10 mL), and the rinsed solutions were
combined with the pooled urine samples collected for
24 h. After measuring the exact volume of the urine
samples, 30 μL aliquots of each sample were stored
at −20°C until analysis.
LC-MS/MS analysis of cimetidine
The concentrations of cimetidine were analyzed using a
modified liquid chromatography tandem mass spectrom-
etry (LC-MS/MS) method reported by Sun et al. [20].
Thirty μL of rat plasma samples, calibration standards, and
quality control (QC) samples were vortex-mixed with
100 μL of tiapride in methanol (5 ng/mL, internal standard,
IS) for 3 min at a high speed. After centrifugation at
13,000 rpm at 4°C for 8 min, 50 μL of the supernatant was
diluted with 50 μL of water. An aliquot (3 μL) was injected
into the LC-MS/MS system. Ten μL of rat urine samples,
urine calibration standards, and QC samples were vortex-
mixed with 1,000 μL of tiapride in methanol (5 μg/mL) for
3 min at high speed. After centrifugation at 13,000 rpm at
4°C for 8 min, 10 μL of the supernatant was diluted with
200 μL of 30% methanol and an aliquot (3 μL) was injected
into the LC-MS/MS system. Plasma calibration standards
were 1–1000 ng/mL and urine calibration standards were
1–200 μg/mL.
The LC-MS/MS system consisted of an Agilent 1200
series (Agilent Technologies, Wilmington, DE, USA)
and a 6460 triple quadrupole mass spectrometer
(Agilent Technologies). Mass Hunter software (Agilent
Technologies) was used for LC-MS/MS system control
and data processing. Separation was performed on a Luna
phenyl-hexyl column (5 μm, 2.1 mm i.d. × 100 mm,
Phenomenex, Torrance, CA, USA) with a gradient
elution of 5% methanol with 10 mM ammonium formate
(mobile phase A) and 95% methanol with 10 mM
ammonium formate (mobile phase B) at a flow rate
of 0.4 mL/min: 30% mobile phase B for 0.5 min, 30%
to 85% mobile phase B for 0.5 min, 85% mobile phase B
for 3.0 min, 85% to 30% mobile phase B for 0.1 min,
30% mobile phase B for 4 min. The column and auto-
sampler were maintained at 50°C and 5°C, respectively.
Electrospray ionization (ESI) source settings for ionization
of cimetidine in the positive mode were as follows: gas
temperature, 350°C; gas flow, 10 L/min; nebulizer, 35 psi;
sheath gas temperature, 330°C; sheath gas flow, 11 L/min,
and capillary voltage, 3500 V. Fragmentation of molecular
ions for cimetidine and tiapride was performed at a
collision energy of 10 eV and 18 eV, respectively.
Selected reaction monitoring (SRM) mode was used for
quantification: m/z 253.1→ 159.1 for cimetidine and m/z
329.1→ 256 for tiapride.
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Figure 1 Inhibitory effect of DA-9801 on the transport activities of OCT1 (A), OCT2 (B), OAT1 (C), OAT3 (D), OATP1B1 (E), OATP1B3 (F),
P-gp (G), and BCRP (H). Inhibitory effect of DA-9801 (1–300 μg/ml) on the uptake of 0.1 μM [3H]methyl-4-phenylpyridinium (MPP+; a substrate
for OCT1 and OCT2), 1 μM [14C]para-aminohippuric acid (PAH; a substrate for OAT1), 0.1 μM [3H]estrone-3-sulfate (ES; a substrate for OAT3, OATP1B1, and
BCRP), 0.1 μM [3H]estradiol-17β-D-glucuronide (EG; a substrate for OATP1B3), and 0.1 μM [3H]digoxin (a substrate for P-gp) were measured. Data point
represents the mean ± SD of three independent experiments. Data were fitted to an inhibitory effect Emax model and the IC50 value was calculated.
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The concentrations of furosemide were analyzed using a
modified LC-MS/MS method reported by Sora et al.
[21]. Thirty μL of rat plasma samples, calibration standards,
and QC samples were vortex-mixed with 100 μL ofTable 1 Pharmacokinetic parameters of cimetidine (10 mg/kg
of 1,000 mg/kg
5 min pre-dose of DA
Control
Tmax (h) 0.700 ± 0.326
Cmax (ng/mL) 652 ± 120
t1/2 (h) 1.12 ± 0.130
AUC8h (μg/mL · h) 1.77 ± 0.314
AUC∞ (μg/mL · h) 1.79 ± 0.313
CL/F (mL/min/kg) 95.2 ± 15.7
Amount excreted in urine (% of dose) 23.2 ± 4.53
*p < 0.05, for the comparison with the control group.
**p <0.01, for the comparison with control group.4-hydroxydiclofenac-d4 in methanol (500 ng/mL, IS)
for 3 min at a high speed. After centrifugation at
13,000 rpm at 4°C for 8 min, 60 μL of the supernatant was
diluted with 40 μL of water. An aliquot (5 μL) was injected
into the LC-MS/MS. Ten μL of rat urine samples,) after co-administration of DA-9801 at a single oral dose
-9801 (n = 5) 2 h pre-dose of DA-9801 (n = 5)
DA-9801 Control DA-9801
2.50 ± 0.707** 0.300 ± 0.112 1.20 ± 1.24
337 ± 100** 995 ± 305 532 ± 175*
1.45 ± 0.620 1.09 ± 0.139 1.20 ± 0.125
1.34 ± 0.154 1.80 ± 0.372 1.78 ± 0.290
1.41 ± 0.122 1.82 ± 0.382 1.82 ± 0.304
119 ± 9.56 94.1 ± 15.5 93.5 ± 13.8
16.3 ± 10.9 24.1 ± 11.2 27.4 ± 3.23
(A) 5 min Pre-dose of DA-9801
Time (h)
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Figure 2 Plasma concentration-time curves of cimetidine.
(A) Plasma concentration profile of cimetidine in rats after oral
administration of 10 mg/kg cimetidine alone (●) and cimetidine with
5 min pre-dose of 1,000 mg/kg DA-9801 (○). (B) Plasma concentration
profile of cimetidine in rats after oral administration of 10 mg/kg
cimetidine alone (●) and cimetidine with 2 h pre-dose of 1,000 mg/kg
DA-9801 (○). Each data point represents the mean ± S.D. of five rats.
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with 1000 μL of 4-hydroxydiclofenac-d4 in methanol
(15 μg/mL) for 3 min at high speed. After centrifugation
at 13,000 rpm at 4°C for 8 min, the aliquot (5 μL) was
injected into the LC-MS/MS. Plasma calibration standards
were 0.02-20 μg/mL and urine calibration standards were
1–200 μg/mL. Separation was performed on a Pinnacle
DB Biphenyl column (3 μm, 2.1 mm i.d. × 50 mm,
RESTEK, USA) using gradient elution of 5% methanol in0.1% formic acid (mobile phase A) and 95% methanol in
0.1% formic acid (mobile phase B) at a flow rate of
0.3 mL/min: 50% mobile phase B for 0.4 min, 50% to 95%
mobile phase B for 0.1 min, 95% mobile phase B for
4.0 min, 95% to 50% mobile phase B for 0.1 min, 50%
mobile phase B for 4.0 min. The column and autosampler
were maintained at 50°C and 5°C, respectively. ESI source
settings for ionization of furosemide and IS in the negative
mode were as follows: gas temperature, 350°C; gas flow,
10 L/min; nebulizer, 35 psi; sheath gas temperature,
350°C; sheath gas flow, 11 L/min, and capillary voltage,
3500 V. Fragmentation of molecular ions for furosemide
and 4-hydroxydiclofenac-d4 was performed at a collision
energy of 7 eV and 4 eV, respectively. SRM mode was used
for quantification: m/z 329.1→ 284.9 for furosemide and
m/z 315.1→ 270.9 for 4-hydroxydiclofenac-d4.
Pharmacokinetic and statistical analyses
In the inhibition studies, the percentages of inhibition
were calculated using the ratio of the transport rate of
probe substrates with or without DA-9801 and the
relevant data were fitted to an inhibitory effect model
[i.e. v ¼ Emax 1− I½ IC50þ I½ 
 
] [22]. Calculations were per-
formed using WinNonlin software (ver. 2.0, Pharsight,
Mountain View, LA).
In the in vivo rat studies, non-compartmental pharmaco-
kinetic analysis was also performed using the WinNonlin
software. The area under the plasma concentration–time
curve (AUC) was calculated using the linear trapezoidal
method. The area from the last datum point to time infinity
(AUC∞) was estimated by dividing the last measured
concentration in plasma by the terminal rate constant.
The terminal elimination half-life (t1/2) and the systemic
clearance (CL/F) were determined.
Statistical significance was analyzed using the Mann–
Whitney U test, and values of p < 0.05 were consid-
ered statistically significant. The SPSS software package
(ver. 19.0, SPSS, Chicago, IL) was used for statistical
analysis.
Results
Inhibitory effect of DA-9801 on the activities of drug
transporters
To characterize the inhibitory effect of DA-9801 on the
uptake transporters, we measured the uptake of represen-
tative substrates for each transporter in HEK293 cells
overexpressing OAT1, OAT3, OCT1, OCT2, OATP1B1,
and OATP1B3 in the presence of DA-9801 (1–300 μg/mL).
DA-9801 inhibited the transport activity of OCT1, OCT2,
OAT3, and OATP1B1 with IC50 values of 106, 174, 48.1,
and 273 μg/mL, respectively (Figure 1A, B, D, and E).
However, DA-9801 did not inhibit 50% of the trans-
port activity of OAT1 and OATP1B3 at its highest
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we could not calculate IC50 values for these trans-
porters (Figure 1C and F). We further examined the
inhibitory effect of DA-9801 on P-gp (MDR1) and
BCRP function, by examining its effect on the B to A
transport rate of digoxin and ES in LLC-PK1-MDR1
cells and LLC-PK1-BCRP cells, respectively. Efflux of
digoxin and ES via P-gp and BCRP, respectively, was not
inhibited by the presence of DA-9801 at concentrations
up to 300 μg/mL (Figure 1G and H).
Effects of DA-9801 on the pharmacokinetics of cimetidine
and furosemide in rats
To assess the relevance of the DA-9801 IC50 values
obtained in vitro to the in vivo DA-9801 herb-drug
interaction with substrates for OCT1, OCT2, and/or
OAT3, cimetidine was selected as a substrate for OCT1,
OCT2 and OAT3 [23] and furosemide for OAT3 [24].
DA-9801 was orally administered 5 min and 2 h prior to
the administration of cimetidine or furosemide.
The AUC8h, AUC∞, CL/F, and t1/2 of cimetidine
were not changed by pre-dose of DA-9801, either at
5 min or 2 h. Consequently, the amount of cimetidine
excreted in urine was not changed by the pretreatment of
DA-9801. In contrast, 5 min pre-dose of DA-9801 delayed
Tmax and decreased Cmax of cimetidine. 2 h pre-dose of
DA-9801 decreased Cmax without affecting Tmax of cimeti-
dine (Table 1 and Figure 2).
In contrast to these cimetidine-related observation, the
pharmacokinetic parameters such as Tmax, Cmax, AUC8h,
AUC∞, CL/F, t1/2, and the amount of furosemide excreted
in urine were not affected by the co-administration of
DA-9801 either 5 min or 2 h prior to furosemide (Table 2
and Figure 3).
Discussion
The recent trend toward the use of poly pharmacy,
which comprises drugs with different mechanisms of
action, necessitates careful consideration of the potential
drug-drug interactions (DDI) between the combinedTable 2 Pharmacokinetic parameters of furosemide (10 mg/k
of 1,000 mg/kg
5 min pre-dose of DA
Control
Tmax (h) 0.600 ± 0.518
Cmax (μg/mL) 1.32 ± 0.330
t1/2 (h) 3.40 ± 1.51
AUC8h (μg/mL · h) 4.00 ± 1.02
AUC∞ (μg/mL · h) 4.91 ± 1.29
CL/F (mL/min/kg) 36.7 ± 13.5
Amount excreted in urine (% of dose) 20.2 ± 7.19medicines. DDIs between inhibitors and substrates of
metabolizing enzymes or transporters can cause serious
adverse reactions. Therefore, prediction and evaluation
of DDI potential is important in the clinic and in the
drug development process.
It is increasingly recognized that drug transporters have
a significant impact on DDIs by modulating the absorption,
distribution, and excretion of drugs, alone or in interaction
with drug-metabolizing enzymes [16,25,26]. In particular,
screening of clinically important drug transporters such as
OCT1, OCT2, OAT1, OAT3, OATP1B1, OATP1B3, P-gp,
and BCRP in the drug development stage is recommended
[16]. In this study, we investigated the inhibitory effects of
DA-9801 on these transporters. IC50 values of DA-9801 for
these transporters were estimated to be 106, 174, >300,
48.1, 273, >300, >300, and >300 μg/mL, respectively
(Figure 1).
It is important to note that in vivo human studies
investigating the interactions between DA-9801 and
substrates for the affected transporters such as OCT1,
OCT2, and OAT3 are necessary to determine whether
the in vitro inhibition of these transporters by DA-9801
is relevant or not. The inhibition of transport activities
in vitro can be applied to herb-drug interaction potential
in vivo with effective highest plasma concentration,
plasma free fraction, and IC50 values of perpetrator [16].
However, DA-9801 is a herbal extract and, this has made
elucidation of a single effective component and its plasma
concentration difficult. Therefore, we aimed to investigate
the in vivo herb-drug interaction potential in rats by using
DA-9801 and either cimetidine, a simultaneous substrate
for OCT1, OCT2, and OAT3, or furosemide, a substrate
for OAT3.
The effective dose of DA-9801 for the therapeutics of
diabetic neuropathy was 100–1,000 mg/kg in rats [6,7].
Therefore, we treated DA-9801 at a dose of 1,000 mg/kg in
this study since the inhibitor has been treated at a max-
imum effective dose to investigate the highest possibility of
in vivo herb-drug interaction. Then, although the experi-
mental systems and species were not perfectly matched,g) after co-administration of DA-9801 at a single oral dose
-9801 (n = 5) 2 h pre-dose of DA-9801 (n = 5)
DA-9801 Control DA-9801
1.35 ± 0.602 0.250 ± 0.000 0.550 ± 0.411
0.896 ± 0.212 1.92 ± 0.619 1.98 ± 0.364
3.95 ± 1.09 3.40 ± 1.43 3.06 ± 0.920
4.94 ± 2.58 4.67 ± 0.819 5.96 ± 1.11
5.61 ± 1.09 5.59 ± 0.528 7.37 ± 1.08
30.5 ± 5.46 30.0 ± 2.73 23.0 ± 3.72
30.4 ± 14.7 17.5 ± 6.87 25.7 ± 5.70
Figure 3 Plasma concentration-time curves of furosemide.
(A) Plasma concentration profile of furosemide in rats after oral
administration of 10 mg/kg furosemide alone (●) and furosemide with
5 min pre-dose of 1,000 mg/kg DA-9801 (○). (B) Plasma concentration
profile of furosemide in rats after oral administration of 10 mg/kg
furosemide alone (●) and furosemide with 2 h pre-dose of 1,000 mg/kg
DA-9801 (○). Each data point represents the mean ± S.D. of five rats.
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transport activity in HEK293 cells overexpressing human
transporters such as OCT1, OCT2 and OAT3, we
continued to evaluate in vivo herb-drug interactions
between DA-9801 and substrates for Oct1, Oct2, and
Oat3 in rats. Even though the tendency for the inhibitory
potency of representative inhibitors in OCT and OATtransporters from different species such as mice, rat,
rabbit, and humans, the IC50 values were different among
them [27,28]. Therefore, we should note that a species
difference in the transport activity between human
and rat may account, in part, for the species difference in
herb-drug interaction between DA-9801 and cimetidine
and furosemide.
Cimetidine is a H2 receptor antagonist used for the
treatment of peptic ulcers and related disorders. It is
eliminated mainly by renal excretion in rats, with 70%
eliminated by 72 h after oral ingestion without significant
metabolism [29]. Cimetidine undergoes extensive tubular
secretion in which Oct1/2 and Oat3 play major roles [23].
In case of 5 min pre-dose of DA-9801, Cmax of cimetidine
was lower and Tmax was greater than those in the control
group. DA-9801 did not affect the AUC8h, AUC∞, CL/F,
and t1/2. With regard to 2 h pre-dose of DA-9801 prior to
cimetidine, Cmax was slightly lower than that in the
control group, but there was no difference in Tmax
between treatment groups (Table 1 and Figure 2). Since
average gastric emptying time in rats was about 30 min
[30], differences in the Cmax and Tmax of cimetidine
between 5 min pre-dose and 2 h pre-dose groups could be
attributed to the presence and absence of DA-9801 in the
stomach. After the removal of DA-9801 from the stomach
(i.e. case of 2 h pre-dose of DA-9801), absorption phase
of cimetidine tend to be similar to that in the control
group. In addition, considering that Oat3 and Oct1/2
were mainly involved in the renal excretion of cimeti-
dine and that CL/F and urinary excretion of cimeti-
dine were not changed, DA-9801 (orally administered
at a dose of 1,000 mg/kg) affected the intestinal
absorption of cimetidine but did not modulate the
elimination pathway, which is mediated by Oat3 and
Oct1/2. This is supported by literature indicating that
cimetidine was well absorbed after oral administration
via paracellular pathway but its absorption was highly
variable. Gastric pH and emptying variability have
been reported to influence the absorption pattern of
cimetidine as a function of dose and time of adminis-
tration [31,32].
Furosemide, an inhibitor of the Na+–K+–2Cl− symport
that is used as loop or high-ceiling diuretic, is eliminated
mainly by renal excretion in rats, with 80-90% elimination
by 72 h after intravenous injection without significant
metabolism [24]. Furosemide undergoes extensive tubular
secretion in which Oat1/3 play major roles [24]. Neither
the 5 min pre-dose nor 2 h pre-dose of DA-9801
affected the pharmacokinetic parameters of furosemide
(i.e., AUC8h, AUC∞, CL/F, t1/2, and amount excreted in
urine). Taking all these results into consideration,
DA-9801, a weak inhibitor of OAT3, did not cause
in vivo herb-drug interactions that affected the
pharmacokinetics of furosemide in rats.
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We have investigated the inhibitory effects of DA-9801 on
transport activities of clinically important transporters
and explored the in vivo herb-drug interaction potential
between DA-9801 and target transporters such as OCT1,
OCT2, and OAT3 at the maximum effective dose of
DA-9801 in rats (1,000 mg/kg). While DA-9801 pre-dose
(5 min or 2 h) did not change the pharmacokinetics of
furosemide, it decreased the Cmax of cimetidine without
changing AUC and CL/F. These results suggested that
inhibitory effects of DA-9801 on OCT1, OCT2, and
OAT3 transporters in vitro may not necessarily translate
into in vivo herb-drug interaction in rats.
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